Evergreen Biosciences

What Evergreen Biosciences does

Evergreen Biosciences is a private biotechnology research center founded in 2018 and headquartered in New York City, with a laboratory facility in Brooklyn. The company is built around its patent-pending Everlast® platform, described as the first pharmaceutical-grade cryoprotectant, which uses chemical biology and small-molecule chemistry to target intracellular mechanisms behind cellular freeze-thaw shock — a mechanistic departure from incumbent DMSO-based cryopreservation. Its product portfolio spans Genetically Engineered Cells (GECs™) distributed through overnight cellular e-commerce, alongside service offerings in organ preservation and tissue banking, cell and gene therapy manufacturing support, biobanking, and cryoprotection consulting.

The company serves academic and research institutions (e.g., MIT, Weill Cornell Medical College) and pharmaceutical and biotechnology customers (e.g., Afraxis) requiring high-quality, consistent post-thaw cells for drug discovery, disease-model research, and IND-enabling work. GECs™ are sold via a direct e-commerce request form for overnight delivery, while cryogenic processing, consulting, and cGMP-oriented manufacturing support are delivered through direct sales engagements. Pricing is not publicly disclosed and appears quote-based given the custom nature of the offerings.

Evergreen Biosciences also articulates a broader vertical ambition — reproductive medicine (eggs/sperm), organ transplant, and human bio-stasis / cryonics — via the Everlast® platform, though commercial maturity in these extensions is not demonstrated. The company operates privately with no disclosed institutional funding or parent entity, maintains one to ten employees based on available headcount and hiring signals, and conducts R&D at its Brooklyn lab while coordinating corporate functions out of its Midtown Manhattan headquarters.

Name

Evergreen Biosciences

Legal name

Evergreen Biosciences, Inc.

Website

https://evergreenbiosciences.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Evergreen Biosciences, founded in 2018 and headquartered in New York, develops the patent-pending Everlast® pharmaceutical cryoprotectant platform and sells Genetically Engineered Cells (GECs™) and cryopreservation services to academic researchers and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Cryopreservation Technology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)

akta.pro secondary industries

Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Cryogenic Logistics (LN2 Dry Shippers, -150°C) (HLAGAMAB), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)

Keywords

• Cryopreservation technology
• Pharmaceutical cryoprotectants
• Genetically engineered cells
• Cell therapy services
• Biobanking services

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cellular E-Commerce Sales: Overnight delivery of Genetically Engineered Cells (GECs™) ready for experiments. Customers can request primary animal cells of any type including custom genetically engineered cells.
2. Cryogenic Processing Services: Cryogenic processing of cellular therapies — from freezing to thawing — to support customers' research. Includes organ cryopreservation, cell therapy support, and biobanking services.
3. Consulting Services: Business development, market analysis, marketing and strategic planning, research design, product and process development, cell expansion and differentiation protocols, quality assurance, regulatory assessment, and commercialization pathway support.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Evergreen Biosciences develops and commercializes the Everlast® pharmaceutical cryoprotectant platform — a chemical-biology approach that uses small molecules to prevent cellular freeze-thaw damage — and produces cryopreserved Genetically Engineered Cells (GECs™) for research applications. The company also offers commercial-stage manufacturing, cryogenic processing, biobanking, and consulting services to biotechnology, pharmaceutical, and academic clients developing advanced medicines and cell-based therapies.

Product overview

Evergreen Biosciences offers a unified platform built around its core Everlast® pharmaceutical cryoprotectant technology, complemented by a portfolio of products and services for the biomedical industry. The Everlast Platform serves multiple verticals (Cell and Gene Therapy, research cells, reproductive medicine, organ transplant, and bio-stasis) using the patent-pending Everlast® cryoprotectant that targets cellular freeze-thaw stress pathways. Genetically Engineered Cells (GECs™) are sold via the Cellular E-commerce channel for overnight delivery, while services cover Organ Preservation and Tissue Banking, Gene & Cell Therapy manufacturing, Organ Cryopreservation, Biobanking, and Cell Production & Cryoprotection Consulting.

Differentiator

Problem solved

Functional benefit

Brands

• Everlast®: Pharmaceutical cryoprotectant technology platform using chemical biology to target cellular responses to freeze/thaw damage with small molecules that penetrate cells instantly.
• GECs™ (Genetically Engineered Cells)

Products and services

• Everlast® Cryoprotectant
• Genetically Engineered Cells (GECs™)
• Cellular E-commerce Delivery Service
• Organ Preservation and Tissue Banking Service
• Gene & Cell Therapy Manufacturing Support
• Organ Cryopreservation Service
• Biobanking Service
• Cell Production & Cryoprotection Consulting

Quantifiable outcome

• Significantly improved post-thaw consistency with reduced percent error of performance across viability, cell size and 3-day functionality tests compared to DMSO controls

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cytiva: Cytiva (formerly GE Healthcare Life Sciences) supplies bioprocessing and cell therapy manufacturing equipment, consumables, and cryopreservation media to the same academic and pharma research customers that Evergreen targets with Everlast®.
• Corning Life Sciences: Corning's Life Sciences segment produces cell culture media, cryogenic storage vials, and cryopreservation products that serve the same research and cell therapy markets as Evergreen's Everlast® and GECs™ lines.
• Sartorius: Sartorius provides bioprocessing equipment and consumables for cell and gene therapy manufacturing, including cell expansion and cryopreservation-adjacent workflows that overlap with Evergreen's services portfolio.
• Lonza Cell & Gene Technologies: Lonza is a global CDMO with cell and gene therapy manufacturing services, including cryopreservation and bioprocessing capabilities that overlap with Evergreen's consulting, cell therapy support, and cryogenic processing services.

Emerging players

• Stemcell Technologies: Stemcell Technologies supplies primary cells, cell culture media, and reagents for biomedical research — directly comparable to Evergreen's GECs™ cellular e-commerce offering and disease-model cell products targeting academic researchers.
• OrganOx: OrganOx develops organ preservation technology (metra®) for liver and other organ transplant applications — directly comparable to Evergreen's stated organ cryopreservation vertical targeting transplant and tissue banking customers.
• X-Therma: X-Therma is an early-stage developer of DMSO-free cryoprotectants and cryopreservation technologies for cells, tissues, and organs — a direct emerging peer to Evergreen's Everlast® small-molecule cryoprotectant platform.

Direct peers

• BioLife Solutions: BioLife Solutions is a leading supplier of cryopreservation media and cold-chain biopreservation tools for cell and gene therapy, regenerative medicine, and biobanking — directly competing with Evergreen's Everlast® platform and GECs™ offerings across the same customer base.
• Cryoport Systems: Cryoport provides temperature-controlled logistics and cryogenic shipping for life sciences, including cell therapies and reproductive medicine — directly comparable to Evergreen's overnight-delivery, cold-chain capabilities for engineered cells and biologics.
• ThermoGenesis Holdings: ThermoGenesis develops automated cell processing and cryopreservation systems for cell therapy and biobanking — directly comparable to Evergreen's cryogenic processing services and cell therapy manufacturing support.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/evergreen-biosciences
• Xx.com/EvergreenBiosci

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evergreen Biosciences